Purpose The purposes of the present study were to classify the palliative care population (PCP) in a comprehensive cancer centre by using information on antineoplastic treatment options and to analyse associations between sociodemographic factors, cancer diagnoses, treatment characteristics and receiving specialist palliative care (SPC). Methods This is a cross-sectional screening study of patients with cancer in the Department of Oncology, Rigshospitalet, Copenhagen University Hospital for 6 months. Patients were assessed to be included in the DOMUS study: a randomised controlled trial of accelerated transition to SPC at home (NCT01885637). The PCP was classified as patients with incurable cancer and limited or no antineoplastic treatment options. Patients with performance status 2-4 were further classified as the essential palliative care population (EPCP). Results During the study period, 3717 patients with cancer were assessed. The PCP comprised 513 patients yielding a prevalence of 14 %. The EPCP comprised 256 patients (7 %). The EPCP was older, more likely inpatients, had a higher comorbidity burden and 38 % received SPC. Women, patients without caregivers and patients with breast cancer were more likely to receive SPC. Conclusions By using objective criteria from clinical data and systematic screening, the observed prevalence of the PCP of 14 % may be generalisable to comprehensive cancer centres with similar composition of cancer diagnoses.
Introduction
Along with a growing research base and increasing availability of palliative healthcare services, the definition of the palliative care population (PCP) is subject to continuous change in the clinical practice due to management strategies ranging from earlier interventions to end-of-life care [1] . Two systematic reviews have investigated the definitions of PCP applied in randomised controlled trials (RCTs) [2, 3] . Van Mechelen et al. included both cancer and non-cancer patients and Sigurdardottir et al. restricted their search to patients with cancer. Regardless of the populations involved, both research groups found a lack of consensus and clarity in the applied definitions of the samples included in RCTs [2, 3] .
In line with this lack of classification of the target population, there is also an urgent need to identify the appropriate time to refer patients for specialist palliative care (SPC). The timing of SPC may be of great significance for clinical outcomes as early referral to SPC seems to be associated with increased possibility of dying at home [4] and also leading to fewer unintentional hospital admissions and deaths [5] . This is underpinned by the findings of Temel et al., who showed that early SPC could enhance the quality of life and prolong survival in a sample of newly diagnosed patients with lung cancer [6] . These results were supported by Zimmermann et al. in a cluster-randomised trial of patients with mixed cancer diagnoses, which also showed improved quality of life [7] . Hence, a classification of the target population is a prerequisite for the integration of SPC in health care services, which currently is highly recommended as a future clinical pathway [8] .
In Denmark, SPC has so far been offered at the end of life with a median survival of 37 days from referral to SPC and 20 % who die between referral and initiation of SPC [9] . Referral criteria are currently not standardised and vary between units, which are both hospice-and hospital-based units. In our region, the Capital Region, nine SPC units operate serving a population of 1.8 million inhabitants. Most units provide inpatient, outpatient and home-based services. The Danish healthcare system including SPC is financed through taxes and free upon receipt.
Healthcare planning on the individual patient level, at the societal level and for research purposes requires unambiguous classification of the PCP to ensure timely and equal opportunities for patients with palliative care needs. This study is an analysis of a patient sample assessed for inclusion in the DOMUS study which is an RCT of accelerated transition from oncological treatment to SPC at home [10] . The aims of the present study were to classify the PCP and the essential PCP (EPCP) by using available information on incurable disease and limited or no antineoplastic treatment options and to analyse associations between socio-demographic factors, the specific cancer diagnoses, treatment characteristics and receiving SPC.
Method Study design, setting and eligibility criteria
The study design is cross-sectional and examines a sample of patients included in the DOMUS database from July 1 to December 31, 2013. The DOMUS study has permission from the Ethics Committee (H-4-2013-016) and the Data Protection Agency (2007-58-0015) and is registered at clinicaltrials.gov (NCT01885637). Patients were assessed for eligibility in the Department of Oncology at Rigshospitalet, Copenhagen University Hospital. All assessed patients lived in the Capital Region and were ≥18 years of age at the time of inclusion in the study. Patients were considered to belong to the PCP if they had incurable disease and limited or no antineoplastic treatment options.
The operational classification of limited or no antineoplastic treatment options was developed for the DOMUS study and includes patients with cancer, who are depleting available lines of treatment as well as patients who decline antineoplastic treatments. This classification was developed through a consensus process in which leading oncologists at the hospital were asked to identify the treatments available for the cancer diagnoses in their field of expertise. The classifications were further synthesised by the consort of the DOMUS study and reintroduced to the oncologists to ensure consensus. The disease-specific classifications of incurable disease and limited treatment options are presented in Table 1 .
Screening procedure
Step 1: On a daily basis, two project nurses specifically trained and allocated to the project reviewed medical records of all inpatients during the study period. Outpatients were screened with a sequential alternation procedure that secured equal screening of all outpatient wards on all weekdays. Step 2: The project nurse or the treating oncologist assessed performance status upon the patients' arrival in the clinic [11] .
Step 3: The data described in the following were collected from the patients' medical records.
Data collection and variables

Living situation
Living situation was categorised as suggested in the European Association for Palliative Care minimal dataset [12] . Living situation was analysed as two groups: 'living with adults' (with spouse/partner, with spouse/partner and children, with other adults, in an institution) and 'not living with adults' (alone, with minor children).
Performance status
Eastern Cooperative Oncology Group (ECOG) performance status (PS) [11] was analysed as dichotomous variables: PS 0-1 and PS 2-4.
Comorbidity
Comorbidity was categorised according to the Charlson Comorbidity Index [13] . Higher score means greater comorbidity load. A variable of psychiatric comorbidity was included as a group consisting of depression, anxiety or substance abuse as documented in the medical records.
Cancer disease
ICD-10 cancer diagnoses were extracted and grouped.
Terminal declaration
Terminal declaration is grounded in a Danish law considering a financial reimbursement for patients with disease refractory to treatment and estimated short life expectancy. The terminal declaration makes all outpatient prescription drugs free of charge. It was categorised as received (yes) or not received (no).
SPC
Contact to SPC is any ongoing connection to a hospice-or hospital-based specialist palliative team (SPT) with an interdisciplinary mode of work and team members with their main focus of work in palliative care [14] . It was categorised as received (yes) or not received (no).
Oncology treatment
Oncology treatment was categorised as 'no active antineoplastic treatment' (treatment pause or supportive care only) or 'active antineoplastic treatment' (chemotherapy, chemotherapy and radiotherapy, radiotherapy, hormonal therapy, surgery or other treatments).
Analysis
For this study, we have elaborated the following classifications to target and analyse the patients in need of SPC:
1. The palliative care population (PCP): patients with incurable cancer disease and limited or no antineoplastic treatment options 2. The essential palliative care population (EPCP): patients with incurable cancer disease, limited or no antineoplastic treatment options and PS of 2-4
The PCP and the EPCP were analysed with chi-square tests and the Wilcoxon Rank test. The association between sociodemographic factors, cancer diagnoses, treatment and receiving SPC was analysed with logistic regression models. The lung cancer group was used as reference group to compare diagnoses since this was the largest group and considered most burdened with symptoms [15] .
All analyses were performed in SAS 9.3. A p value of≤ 0.05 was considered significant.
Results
Classification of PCP and EPCP
During the study period, 3717 patients in the comprehensive cancer centre were assessed for inclusion in the PCP and EPCP. The populations are illustrated in Fig. 1 .
The PCP comprised the 513 patients with incurable disease and limited antineoplastic treatment options yielding a prevalence of 14 % of the total assessed sample. The majority of patients were women (57 %) and mean age of the PCP was 65 years (SD 12). Most patients lived with other adults (62 %). The largest diagnostic group was patients with lung cancer (29 %) followed by gastrointestinal cancer (21 %) and CNS and breast cancer (14 %). The most prevalent comorbidity was chronic pulmonary disease (13 %) followed by diabetes (8 %). More than 9 % of the patients had a documented psychiatric comorbidity. Almost 20 % were inpatients and 29 % received SPC. Most (57 %) received chemotherapy. Characteristics of the PCP are shown in Table 2 .
The EPCP comprised 256 patients yielding a prevalence of 7 % of the total assessed sample ( Table 2 ). Compared to patients with PS 0-1, the EPCP was older, more often diagnosed with lung cancer (37 vs. 21 %), equally often diagnosed with gastrointestinal and breast cancer and less often with CNS cancer (11 vs. 17 %). The EPCP had a higher comorbidity burden and was more often inpatients. At the time of screening, 38 % of the EPCP already received SPC. Further, the EPCP more often had a terminal declaration (p=0.0006) compared to those with PS 0-1. Finally, the EPCP less often received active antineoplastic treatment (p=0.0002) and was more often on a treatment pause or received supportive care only.
Receiving SPC
One hundred and forty-seven patients received SPC (Table 3) . Women were more likely to receive SPC (OR, 2.6; 95 % CI, 1.6-4.3) than men. In another logistic regression analysis, the sex-specific diagnoses (breast, female and male genitalia) were removed leaving 377 patients for further analysis. The effect of sex remained prominent (OR, 2.2; 95 % CI, 1.3-3.9). There was no significant effect of age, but patients who lived without other adults (OR, 1.6; 95 % CI, 1.1-2.5) were more likely to receive SPC.
Patients with CNS cancer or female genitalia cancer (both OR, 0.2; 95 % CI, 0.1-0.5) were less likely to receive SPC than patients with lung cancer. A secondary logistic regression analysis was modelled after breast cancer. Patients with breast cancer were more likely to receive SPC than patients with any other cancer diagnosis. In an adjusted analysis, the difference remained significant when comparing patients with breast cancer with patients with cancer in the CNS or female genitalia (both OR, 0.1; 95 % CI, 0-0.3). Out of the patients receiving SPC, 66 % had PS 2-4 (OR, 3.1; 95 % CI, 2-4.9). There was a significant association between having obtained terminal declaration and receiving SPC (OR, 5.6; 95 % CI, 3.5-9), and those who were not in active antineoplastic treatment were more likely to receive SPC (OR, 2.1; 95 % CI, 1.3-3.4).
Discussion
Classification of PCP and EPCP To our knowledge, this is the first attempt to classify the PCP in a comprehensive cancer centre. Of course, resources and availability and access to SPC can determine the target PCP ranging from earlier interventions to end-of-life care; however, even in resource rich countries like Denmark, SPC is not sufficiently developed to allow for earlier interventions in a large scale, and, therefore, the interventions are often based on symptom complaints. Further, a nationally representative study (n=977 from 54 hospital departments) coming out of Denmark demonstrated that patients with advanced cancer (stage 3 or 4), who were not in SPC, suffered from a prevalent and severe symptom burden [16] . The method used to classify the PCP presented here allows for an estimate of the prevalence and timely identification of patients that may need SPC. All patients visiting the clinic had an equal chance of being screened for eligibility. Due to the systematic patient screening and objective criteria for classification, the observed prevalence of 14 % may be generalisable to comprehensive cancer centres with similar composition of cancer diagnoses and may be applicable even to centres admitting other diagnoses. This classification of PCP was based on cancer diagnose-specific incurable disease and limited antineoplastic treatment options as a concretisation of the unspecified definition 'life-threatening illness' as presented by the WHO [17] .
Neither the WHO definition nor the present concretisation includes a description of patients' quality of life and symptom load. In addition to a life-threatening illness, a PCP may also be defined by patients' and caregivers' needs and their complexity. Needs may often but not always be related to illness and curability. Patient-reported needs may arise from symptom/problem intensity, burden and experienced need [18] , however, also from patient expectations. Healthcare professionals' judgment of complexity may rely on available healthcare resources and capacity for general palliative care. Furthermore, the concept of unmet need should be viewed in light of the healthcare systems ability to meet expressed need, which is often not the case in incurable disease. The many contingencies and perspectives on needs make definition generalisability difficult, but further characterisation of the PCP would benefit from employing various perceptions of the topic. So far, previous studies have mainly investigated symptom/problem intensity and burden and shown a high prevalence of symptoms/problems in samples somewhat similar to the PCP. For example, in the UK, 83 % of 480 outpatients with cancer reported one or more problems likely to benefit from SPC [15] . In a Danish sample of patients with advanced cancer, the most prevalent problems were fatigue, limitations in physical and daily activities, worry, difficulties with sexuality and pain (52-73 %), and felt need in the same areas varied between 23 and 35 % [19] . Most patients in the PCP are expected to be burdened with symptoms and/or have a need for palliative care. Almost 40 % of the EPCP received SPC, which indicates substantial palliative care needs in this group. Fifty percent of the EPCP had SPC and/or a terminal declaration indicating that clinicians had recognised that half of the EPCP patients were in the palliative care phase. The clinical relevance of this moderately fulfilled observation is further underpinned by the apparent frailty of the group, which is burdened with higher levels of comorbidity, poorer PS and older age and more often, being inpatients. Poorer PS may likely represent a decline in health status and has previously been identified among the most important predictors of poor prognosis [20] . Better PS has been used to select patients for early palliative care [6, 7] . For that reason, the EPCP probably represents a group of cancer patients with a more urgent need of SPC that should have a high priority when planning and organising SPC in a comprehensive cancer centre. Attempts to classify the PCP across diagnoses may lead to ambiguity and lack of reproducibility. This may be the case in survival prognostication, which is widely used as inclusion criteria in clinical trials [2, 3] . Although survival prognostication correlates with patients' actual survival, it is also inaccurate and tends to overestimate patients' survival [21] . Even if survival prognostications were regularly documented in clinical practice, the tendency to overestimate could involve missed opportunities for timely referrals to SPC. Extent of disease is also widely used as inclusion criteria in clinical trials of cancer PCP. However, it is questionable if advanced stage of cancer itself can be judged imminently life-threatening considering the increasing number of available treatments to control, but not to cure the disease-a scenario which is particularly relevant in breast cancer [22] . The life-threatening perspective may not present itself clearly until treatment options are depleted. Refractoriness to chemotherapy in metastatic cancer has previously been used to select a sample in a prospective cohort study of end-of-life care [23] . Thus, with the availability of increasing number of lines of chemotherapy, it may therefore be preferable to add the term 'limited antineoplastic treatment options' to incurable cancer. The external validity of the present classification of PCP eludes determination due to lack of consensus and reference.
Receiving SPC
We observed that women were more likely to receive SPC than men also in an analysis of only non-sex-specific diagnoses. This is in line with other studies of sex differences in which women are more likely to receive palliative care at home [24] . Sex, however, does not fully explain why breast cancer patients were more likely to receive SPC than other patients with cancer. A possible explanation may be the prolonged survival in breast cancer patients allowing them to discover and use available healthcare services. Patients with CNS cancer report high needs for palliative care [15] but remarkably, seldom receive SPC. Possibly, the neurology departments provide them with additional supportive care compared to patients with other cancers. Some SPC units require patients to be well-informed about their prognosis, which is difficult in the face of cognitive deficits. Timing of referral to SPC may also seem challenging since disease trajectories can be unpredictable with multiple recurrences and prolonged functional impairment [25] . The noticeable differences between diagnosis groups may also stem from the culture of the healthcare professionals that specialise in the management of specific cancer diagnoses, particularly since this is a single centre study.
Patients who lived without caregivers were more likely to receive SPC. Living without an informal caregiver may increase the need for professional caregiving and patients who live alone are more likely to receive home care services [26] . In contrast, previous studies have demonstrated a positive correlation between being married and receiving SPC [27] , which is surprising since marriage in most cases should not involve increasing care needs. The conflicting findings may be due to the retrospective design of other studies and the crosssectional design of the present study. It is possible that married patients are referred at a later stage in the disease trajectory The DOMUS study, Denmark PS performance status, ns not significant and single patients are referred at an earlier stage. Regional or national differences in referral practices may also explain the variation. The need for continued research in referral practices to SPC and for policies that support relevant referrals is warranted. Particularly, prospective studies that include PCP before referral to SPC would offer valuable insight. 
Policy and research implications
One may assume that referral to SPC is based on patients' prognosis or current or future needs for symptom control [28] . Patients' symptom burden may depend upon the skills and capacity of the general healthcare system and is subject to assessment by referring healthcare professionals and by the SPT. The lack of systematic assessment of palliative care needs in clinical practice in Denmark creates the possibility for biased referrals to SPC. The difference in diagnoses and in sex in patients receiving SPC may question the appropriateness of the current referral practice. The criteria and screening procedure used in the present study to select PCP may also be used proactively to identify patients for SPC during the oncology treatment trajectory, and diagnose-specific classification of PCP seems to be a preferable alternative to, for example, survival prognostications. The addition of systematic screening for palliative care needs to our screening procedure could, apart from targeting therapy, further strengthen and clarify the identification of populations in need of SPC in a comprehensive cancer centre.
The EPCP can serve as a standard for patients, who as a minimum should be considered for SPC, and the PCP can serve as a standard for patients to be considered for SPC in a healthcare system with a well-developed palliative care programme. The clinical practice in our comprehensive cancer centre has already taken a step in that direction with almost 30 % of the PCP and almost 40 % in the EPCP receiving SPC, respectively. The present study did not include all cancer diagnoses as they are managed in other hospitals in the region, and more research to define PCP in other environments is warranted. Adapted versions of limited treatment options could be applied to any cancer diagnosis and, potentially, also to non-malignant diseases to identify PCP.
Conclusion
Using objective criteria from clinical data may be a feasible method to identify the PCP. Due to the systematic screening, the observed prevalence of the PCP was 14 % and EPCP 7 % in a comprehensive cancer centre. The EPCP was older, more often inpatients, more often had lung cancer and had a higher burden of comorbidity. The EPCP was more often on a treatment pause and 38 % received SPC. Being a woman, living alone, a diagnosis of breast cancer, worse PS, terminal declaration and less active antineoplastic treatment were associated with receiving SPC.
